Why the study?
Previous studies investigating cardiac remodeling and functional regurgitation of rhythm control for AF in HF were limited.
Does rhythm control improve cardiac remodeling, functional regurgitation, and clinical outcomes compared to rate control in patients with atrial fibrillation and heart failure?
Does rhythm control improve cardiac remodeling, functional regurgitation, and clinical outcomes compared to rate control in patients with atrial fibrillation and heart failure?
Rhythm control for atrial fibrillation in heart failure patients is associated with improved cardiac remodeling, reduced functional regurgitation, and better clinical outcomes, particularly in HFpEF and HFrEF.
Observational data suggest rhythm control may aid remodeling in HF-AF; leaves open prospective confirmation for regurgitation and prognosis.
PURPOSE: Previous studies investigating cardiac remodeling and functional regurgitation of rhythm control for atrial fibrillation (AF) in heart failure (HF) are limited. Therefore, this study aimed to evaluate the impact of rhythm control for AF on cardiac remodeling and functional regurgitation in the spectrum of HF. Its effect on prognosis was explored. METHODS: According to the treatment strategies of AF, the cohort was classified into the rhythm control and rate control groups. To further detect the implications of rhythm control on cardiac remodeling, functional regurgitation, and outcomes in HF subtypes, patients were further divided into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction, and HF with preserved ejection fraction (HFpEF) subgroups. RESULTS: A total of 828 patients were enrolled, with 307 patients in the rhythm control group and 521 patients in the rate control group. Over a median follow-up time of 3.8 years, patients with rhythm control treatments experienced improvements in biatrial structure parameters, left ventricular ejection fraction, and functional regurgitation (mitral and tricuspid regurgitation) compared with rate control treatment (p < 0.05). Cox regression analysis demonstrated that rhythm control reduced the risks of all-cause mortality (HR 0.436 [95% CI, 0.218-0.871], p = 0.019) in HFpEF and HF-related admissions in HFrEF (HR 0.500 [95% CI, 0.330-0.757], p = 0.001) and HFpEF (HR 0.541 [95% CI, 0.407-0.720], p < 0.001); these associations were similar after adjusting for multiple confounders. CONCLUSIONS: Rhythm control therapy can be considered an appropriate treatment strategy for the management of AF in HF to improve cardiac remodeling, functional regurgitation, and prognosis.
No takes yet. Share an insight, caveat, or question.
Si et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: